Avedro’s KXL® System for accelerated cross-linking, as well as a family of riboflavin products, have been commercially available since 2010. Refractive correction pioneer and veteran David Muller, PhD, President & CEO, discussed the company’s most recent activities, expressing excitement about Avedro’s PiXL, a non-invasive refractive correction procedure, which uses only eye drops and light. Among other efforts, the company is also developing a Brillion Microscopy system, which would be the first device to measure biomechanical parameters in the eye (on track for 510k submission 4Q 2015).
David Muller, PhD
Dr. Muller recognized the potential of using advanced methods to gently reshape the cornea and in 2007 founded Avedro, Inc., where he serves as the CEO.